Skip to main content
. 2022 Jan 12;8(2):eabj8207. doi: 10.1126/sciadv.abj8207

Fig. 7. Therapeutic effect of SPION-NNV-DOX on tumor-bearing NCG mouse.

Fig. 7.

(A) Schematic design for SPION-NNV-DOX treatment in subcutaneous xenograft tumor model established by SW480 cells in NCG mice. (B) Representative images of ex vivo fluorescent signals in the major organs (heart, liver, spleen, lung, and kidney) and tumors of mice at 3 days after the last injection. (C) Images of SW480 xenograft tumors in NCG mice treated with PBS, DOX-CL (5 mg/kg of body weight), SPION-Ex (5 mg/kg of body weight) with or without MF, SPION-NNV (5 mg/kg of body weight) with or without MF, and SPION-NNV-DOX (5 mg/kg of body weight, DOX) with or without MF under 7 cycles of treatment regimen (n = 7 per group; 4 days/cycle). (D) Tumor volume was closely monitored and tumor growth curves were recorded. (E) Tumor weights of mice in each group at the end of study (day 39). (F and G) Representative images of Ki-67 (F) and TUNEL (G) staining of tumors in each group. (H and I) Statistical analyses of immunohistochemical staining results. (J) Schematic illustration of SPION-Ex and exosome-like NVs as a novel cancer therapeutic agent and drug delivery nanoplatform. Scale bars, 100 μm. One-way ANOVA for multiple groups were applied for statistical analysis. *P < 0.05 and ***P < 0.001.